> top > docs > PMC:7253235 > spans > 39896-43184 > annotations

PMC:7253235 / 39896-43184 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T7 2045-2048 https://glytoucan.org/Structures/Glycans/G00063MO denotes CAD

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1371 2316-2320 Gene denotes HER2 Gene:2064
1372 2322-2326 Gene denotes BRAF Gene:673
1373 2327-2330 Gene denotes MEK Gene:5609
1374 323-330 Species denotes patient Tax:9606
1375 436-443 Species denotes patient Tax:9606
1376 718-728 Species denotes outpatient Tax:9606
1377 1271-1279 Species denotes patients Tax:9606
1378 1846-1854 Species denotes patients Tax:9606
1379 2243-2251 Species denotes patients Tax:9606
1380 2435-2443 Species denotes Patients Tax:9606
1381 2640-2648 Species denotes patients Tax:9606
1382 3002-3009 Species denotes patient Tax:9606
1383 3036-3044 Species denotes patients Tax:9606
1384 92-100 Disease denotes COVID-19 MESH:C000657245
1385 129-135 Disease denotes cancer MESH:D009369
1386 296-302 Disease denotes cancer MESH:D009369
1387 351-359 Disease denotes COVID-19 MESH:C000657245
1388 362-368 Disease denotes Cancer MESH:D009369
1389 584-592 Disease denotes COVID-19 MESH:C000657245
1390 697-703 Disease denotes cancer MESH:D009369
1391 841-847 Disease denotes cancer MESH:D009369
1392 972-980 Disease denotes COVID-19 MESH:C000657245
1393 1181-1186 Disease denotes tumor MESH:D009369
1394 1401-1415 Disease denotes Cardiotoxicity MESH:D066126
1395 1435-1441 Disease denotes cancer MESH:D009369
1396 1460-1474 Disease denotes cardiomyopathy MESH:D009202
1397 1476-1487 Disease denotes arrhythmias MESH:D001145
1398 1493-1501 Disease denotes ischemic MESH:D007511
1399 1529-1535 Disease denotes cancer MESH:D009369
1400 1589-1597 Disease denotes COVID-19 MESH:C000657245
1401 1611-1629 Disease denotes cardiac and cancer MESH:D006338
1402 1654-1663 Disease denotes mortality MESH:D003643
1403 1905-1908 Disease denotes CVD MESH:D002318
1404 1963-1975 Disease denotes dyslipidemia MESH:D050171
1405 2050-2061 Disease denotes arrhythmias MESH:D001145
1406 2066-2069 Disease denotes CHF
1407 2193-2219 Disease denotes arrhythmias Cardiotoxicity MESH:D066126
1408 2236-2242 Disease denotes cancer MESH:D009369
1409 2286-2292 Disease denotes cancer MESH:D009369
1410 2455-2469 Disease denotes cardiotoxicity MESH:D066126
1411 2521-2535 Disease denotes cardiotoxicity MESH:D066126
1412 2757-2771 Disease denotes cardiotoxicity MESH:D066126
1413 2950-2962 Disease denotes dyslipidemia MESH:D050171
1414 3153-3156 Disease denotes CHF
1415 3189-3195 Disease denotes cancer MESH:D009369

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T116 270-284 Body_part denotes immune systems http://purl.org/sig/ont/fma/fma9825
T117 1136-1149 Body_part denotes immune system http://purl.org/sig/ont/fma/fma9825
T118 3064-3068 Body_part denotes face http://purl.org/sig/ont/fma/fma24728
T119 3072-3076 Body_part denotes face http://purl.org/sig/ont/fma/fma24728
T120 3114-3119 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T121 3129-3134 Body_part denotes lipid http://purl.org/sig/ont/fma/fma67264

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T53 270-284 Body_part denotes immune systems http://purl.obolibrary.org/obo/UBERON_0002405
T54 1136-1149 Body_part denotes immune system http://purl.obolibrary.org/obo/UBERON_0002405
T55 3064-3068 Body_part denotes face http://purl.obolibrary.org/obo/UBERON_0001456
T56 3072-3076 Body_part denotes face http://purl.obolibrary.org/obo/UBERON_0001456
T57 3114-3119 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T399 92-100 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T400 129-135 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T401 296-302 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T402 351-359 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T403 362-368 Disease denotes Cancer http://purl.obolibrary.org/obo/MONDO_0004992
T404 584-592 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T405 697-703 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T406 841-847 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T407 972-980 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T408 1181-1186 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T409 1435-1441 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T410 1460-1474 Disease denotes cardiomyopathy http://purl.obolibrary.org/obo/MONDO_0004994
T411 1476-1487 Disease denotes arrhythmias http://purl.obolibrary.org/obo/MONDO_0007263
T412 1529-1535 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T413 1589-1597 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T414 1623-1629 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T415 1952-1955 Disease denotes HTN http://purl.obolibrary.org/obo/MONDO_0005044
T416 1963-1975 Disease denotes dyslipidemia http://purl.obolibrary.org/obo/MONDO_0002525
T417 2045-2048 Disease denotes CAD http://purl.obolibrary.org/obo/MONDO_0005010|http://purl.obolibrary.org/obo/MONDO_0018922
T419 2050-2061 Disease denotes arrhythmias http://purl.obolibrary.org/obo/MONDO_0007263
T420 2066-2069 Disease denotes CHF http://purl.obolibrary.org/obo/MONDO_0005009
T421 2193-2204 Disease denotes arrhythmias http://purl.obolibrary.org/obo/MONDO_0007263
T422 2236-2242 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T423 2286-2292 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T424 2950-2962 Disease denotes dyslipidemia http://purl.obolibrary.org/obo/MONDO_0002525
T425 3153-3156 Disease denotes CHF http://purl.obolibrary.org/obo/MONDO_0005009
T426 3189-3195 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T304 208-211 http://purl.obolibrary.org/obo/CLO_0002199 denotes CAR
T305 270-284 http://purl.obolibrary.org/obo/UBERON_0002405 denotes immune systems
T306 593-600 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T307 960-967 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T308 1136-1149 http://purl.obolibrary.org/obo/UBERON_0002405 denotes immune system
T309 1686-1693 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T310 2810-2817 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T311 3064-3068 http://purl.obolibrary.org/obo/UBERON_0001456 denotes face
T312 3072-3076 http://purl.obolibrary.org/obo/UBERON_0001456 denotes face
T313 3114-3119 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T314 3114-3119 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T115 460-468 Chemical denotes carriers http://purl.obolibrary.org/obo/CHEBI_78059
T116 1737-1745 Chemical denotes carriers http://purl.obolibrary.org/obo/CHEBI_78059
T117 2327-2330 Chemical denotes MEK http://purl.obolibrary.org/obo/CHEBI_28398
T118 2543-2557 Chemical denotes anthracyclines http://purl.obolibrary.org/obo/CHEBI_48120|http://purl.obolibrary.org/obo/CHEBI_49322
T120 3129-3134 Chemical denotes lipid http://purl.obolibrary.org/obo/CHEBI_18059

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T28 2141-2147 http://purl.obolibrary.org/obo/GO_0048511 denotes rhythm

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T216 7-15 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T217 129-135 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T218 296-302 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T219 362-368 Phenotype denotes Cancer http://purl.obolibrary.org/obo/HP_0002664
T220 697-703 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T221 841-847 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T222 1025-1033 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T223 1034-1042 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T224 1181-1186 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T225 1435-1441 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T226 1460-1474 Phenotype denotes cardiomyopathy http://purl.obolibrary.org/obo/HP_0001638
T227 1476-1487 Phenotype denotes arrhythmias http://purl.obolibrary.org/obo/HP_0011675
T228 1529-1535 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T229 1558-1566 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T230 1623-1629 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T231 1963-1975 Phenotype denotes dyslipidemia http://purl.obolibrary.org/obo/HP_0003119
T232 2050-2061 Phenotype denotes arrhythmias http://purl.obolibrary.org/obo/HP_0011675
T233 2066-2069 Phenotype denotes CHF http://purl.obolibrary.org/obo/HP_0001635
T234 2193-2204 Phenotype denotes arrhythmias http://purl.obolibrary.org/obo/HP_0011675
T235 2236-2242 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T236 2286-2292 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T237 2950-2962 Phenotype denotes dyslipidemia http://purl.obolibrary.org/obo/HP_0003119
T238 3153-3156 Phenotype denotes CHF http://purl.obolibrary.org/obo/HP_0001635
T239 3189-3195 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T251 0-109 Sentence denotes Cardio-oncology aspect of care Theoretical areas of concern Proposed Strategies to Mitigate COVID-19 Exposure
T252 110-359 Sentence denotes Initiating/ongoing cancer treatments (i.e., chemotherapy, targeted therapies, immunotherapy, BMT, CAR-T), and timing of oncologic-related surgery • Compromised immune systems induced by cancer treatments may make patient more susceptible to COVID-19
T253 360-480 Sentence denotes • Cancer treatments may require healthcare facility/inpatient stay exposing patient to asymptomatic carriers (i.e., HCW)
T254 481-572 Sentence denotes • Delaying of potential critical, life-prolonging surgery as it may be deemed as “elective”
T255 573-783 Sentence denotes • Ensuring COVID-19 testing adequacy by healthcare providers • Implementation of universal PPE and social distancing during cancer treatments in outpatient/inpatient settings, and with family members/caretakers
T256 784-919 Sentence denotes • Weighing risk-benefit of postponing/delaying timing of cancer treatments/surgery to minimize exposure to inpatient healthcare setting
T257 920-980 Sentence denotes • Preoperative/procedural screening and testing for COVID-19
T258 981-1079 Sentence denotes • Telemedicine for routine follow-up cardio-oncology/oncology visits unless clinically symptomatic
T259 1080-1194 Sentence denotes • Research efforts investigating earlier utilization of immune system restorative measures post anti-tumor therapy
T260 1195-1313 Sentence denotes • Consideration of delaying myeloablative therapies and immunotherapies for patients in clinical remission if possible
T261 1314-1400 Sentence denotes • Consideration of minimizing surveillance/staging imaging during and after treatments
T262 1401-1663 Sentence denotes Cardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality
T263 1664-1826 Sentence denotes • Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms
T264 1827-1976 Sentence denotes • Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)
T265 1977-2122 Sentence denotes • Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary
T266 2123-2204 Sentence denotes • Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias
T267 2205-2432 Sentence denotes Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)
T268 2433-2668 Sentence denotes • Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic
T269 2669-2830 Sentence denotes • Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable
T270 2831-2904 Sentence denotes • Limited imaging protocols to evaluate LVEF to minimize acquisition time
T271 2905-3009 Sentence denotes • Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient
T272 3010-3157 Sentence denotes • Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)
T273 3158-3288 Sentence denotes • Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms